Conflict and kala-azar: Determinants of adverse outcomes of kala-azar among patients in Southern Sudan

被引:128
作者
Collin, S
Davidson, R [1 ]
Ritmeijer, K
Keus, K
Melaku, Y
Kipngetich, S
Davies, C
机构
[1] Northwick Pk Hosp & Clin Res Ctr, Dept Infect & Trop Med, Lister Unit, Harrow HA1 3UJ, Middx, England
[2] London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England
[3] Med Sans Frontieres Holland, Amsterdam, Netherlands
关键词
D O I
10.1086/381203
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analyzed data obtained from 3365 patients with kala-azar (KA) or post-KA dermal leishmaniasis (PKDL) treated by Medecins Sans Frontieres-Holland in south Sudan from October 1998-May 2002. Patients were malnourished (median body mass index [BMI], 15.5; median weight for height [WFH], 75.5%) and anemic (median hemoglobin (Hb) level, 8.5 g/dL). The proportion of patients with primary KA who were children <5 years old increased from 2.5%, in 1998, to 19.8%, in 2002 (P < .0001). Therapy with sodium stibogluconate cured 91.9% of patients with primary KA, and dosages of >850 mg per day did not decrease the chances of survival. Risk factors for death among adults were age greater than or equal to45 years (odds ratio [OR], 4.6), malnutrition (BMI, <13; OR, 11.0), anemia (Hb level, <8 g/dL; OR, 4.0), and duration of illness (duration, greater than or equal to5 months; OR, 2.3). Risk factors for death among children and adolescents were age <2 years (OR, 5.4,), malnutrition (WFH, <60%; OR, 5.0), anemia (Hb level, <6 g/ dL; OR, 3.7), and splenomegaly (OR, 2.9). A higher risk of death was associated with episodes of diarrhea (OR, 1.4), vomiting (OR, 2.7), and bleeding (OR, 2.9). Relapse and PKDL occurred in 3.9% and 10.0% of cases, respectively.
引用
收藏
页码:612 / 619
页数:8
相关论文
共 14 条
[1]   Leishmaniasis in Sudan 1. Cutaneous leishmaniasis [J].
El-Hassan, AM ;
Zijlstra, EE .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 :S1-S17
[2]   Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan [J].
Griekspoor, A ;
Sondorp, E ;
Vos, T .
HEALTH POLICY AND PLANNING, 1999, 14 (01) :70-76
[3]  
Hackett L. W., 1944, JOUR NATION MALARIA SOC, V3, P121
[4]   Visceral leishmaniasis and HIV in Tigray, Ethiopia [J].
Lyons, S ;
Veeken, H ;
Long, J .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2003, 8 (08) :733-739
[5]  
*MSF, 1999, MAN DIAGN TREATM VIS
[6]  
MSF, 2002, VIOL HLTH ACC AID UN
[7]   INCRIMINATION OF PHLEBOTOMUS (LARROUSSIUS) ORIENTALIS AS A VECTOR OF VISCERAL LEISHMANIASIS IN WESTERN UPPER NILE PROVINCE, SOUTHERN SUDAN [J].
SCHORSCHER, JA ;
GORIS, M .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1992, 86 (06) :622-623
[8]   EPIDEMIC VISCERAL LEISHMANIASIS IN SUDAN - A RANDOMIZED TRIAL OF AMINOSIDINE PLUS SODIUM STIBOGLUCONATE VERSUS SODIUM STIBOGLUCONATE ALONE [J].
SEAMAN, J ;
PRYCE, D ;
SONDORP, HE ;
MOODY, A ;
BRYCESON, ADM ;
DAVIDSON, RN .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (03) :715-720
[9]   Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources [J].
Seaman, J ;
Mercer, AJ ;
Sondorp, HE ;
Herwaldt, BL .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (07) :664-672
[10]   The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan: Course and impact from 1984 to 1994 [J].
Seaman, J ;
Mercer, AJ ;
Sondorp, E .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1996, 25 (04) :862-871